BioNTech Shares Fall After Phase 2 Colorectal Cancer Trial Halted
BioNTech shares dropped sharply after the company said it would terminate its Phase 2 trial BNT122-01 evaluating autogene cevumeran in ctDNA-positive, surgically resected Stage II or III colorectal cancer. An independent Data Safety Monitoring Board recommended stopping the study after a numerical imbalance in overall survival between the treatment…